Interstitial Lung Disease Remains Major Diagnostic Challenge

Veracyte, Inc.recently presented four abstracts  on current diagnostic challenges related to interstitial lung disease (ILD) and the potential for improved diagnostic procedures using novel genomic-based strategies. The abstracts were given at the Pulmonary Fibrosis Foundation’s PFF Summit 2015: From Bench to Bedside at the JW Marriott Hotel in Washington, D.C., in…

Learn more about Approved IPF Therapies Ofev and Esbriet. Read more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ…

1. Pulmonary Fibrosis Foundation Sets Scientific Record at Upcoming Summit 2. Lung Stem Cell Spheroids Could Offer Cheap, Rapid Pulmonary Fibrosis Therapy 3. Genentech to Help Support Pulmonary Fibrosis Foundation Programs…

Boehringer Ingelheim recently announced new positive data on the company’s FDA-approved therapy OFEV® (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF). The results were presented at the Pulmonary Fibrosis Foundation’s PFF Summit 2015 in Washington, D.C. OFEV is a tyrosine-kinase inhibitor (TKI) that targets growth factors, such as the vascular endothelial…

“Dot Delarosa always had a challenging life, but things got worse when she found out that she had Pulmonary Fibrosis. She needed a lung transplant immediately, or she would die. This is her story.” Learn more Pulmonary Fibrosis: https://bit.ly/1lfMsiZ…

The nonprofit phaware global association (phaware), an organization focused on raising awareness of pulmonary hypertension, has developed a new mobile app (phaware365) to help achieve its goal globally through an innovative and engaging strategy. Pulmonary hypertension (PH) is a life-threatening cardiopulmonary disorder characterized by an abnormally high blood pressure in the…

Singer-songwriter Mary Barry posted on Facebook that she’s been suffering for almost two years with Pulmonary Fibrosis. The Canadian singer felt it was about time to open up to her friends, family and fans about the deadly disease she has been struggling with. On her Facebook post she says: “Inspired by the…

Genentech, a member of the Roche Group, recently presented two abstracts on the company’s product Esbriet (pirfenidone), an oral drug developed for the treatment of pulmonary fibrosis (PF), at the American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada. Both abstracts were…

Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was one of the first two drugs to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung Disease…

Learn more about Idiopathic Pulmonary Fibrosis: https://bit.ly/1QiRmr3…